GURU.Markets stock price, segment price, and overall market index valuation
The company's share price GTHX
GSE Systems provides software and simulators for the energy industry, primarily for nuclear power plants. Its stock price reflects demand for personnel training and improved safety at nuclear power plants.
Share prices of companies in the market segment - General oncology therapy
G1 Therapeutics is a biopharmaceutical company focused on developing and commercializing drugs that improve treatment outcomes for cancer patients. We have classified it in the "General Oncology" segment. The chart below shows how the market values companies working in the supportive care field.
Broad Market Index - GURU.Markets
G1 Therapeutics is an oncology company that has developed a drug to protect bone marrow from damage during chemotherapy. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how G1 shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
GTHX - Daily change in the company's share price GTHX
For G1 Therapeutics, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reactions to sales data for its drugs and the results of new clinical trials.
Daily change in the price of a set of shares in a market segment - General oncology therapy
G1 Therapeutics is a biopharmaceutical company developing drugs to improve cancer treatment outcomes. Oncology is a highly volatile sector driven by clinical trial results. The chart below shows the average fluctuations in this industry, providing context for evaluating GTHX stock.
Daily change in the price of a broad market stock, index - GURU.Markets
G1 Therapeutics is a biotech company specializing in the development of targeted therapies for cancer treatment. Its shares are buoyed by anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization GTHX
G1 Therapeutics, Inc.'s year-over-year performance is a story about the commercialization of its drug, Cosela. Its market capitalization growth over the past 12 months reflects the sales volume of this unique drug, which protects bone marrow from damage during chemotherapy. Its valuation is a bet on it becoming a standard treatment in oncology practice.
Annual dynamics of market capitalization of the market segment - General oncology therapy
G1, a biotech company, focuses on developing drugs to improve chemotherapy outcomes. Its performance relative to the sector will demonstrate the success of its commercial strategy for niche but important oncology drugs and how it is impacted by new research results.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
G1 Therapeutics, with its commercial cancer drug, demonstrates the dynamic transition from development to sales. Its performance relative to the market is an investor assessment of how successfully the company is bringing its product to market and increasing its competitive advantage.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization GTHX
G1 Therapeutics is a commercial-stage oncology company. Its monthly performance reflects both sales growth of its approved drug Cosela and progress in its clinical pipeline. Quarterly revenue reports and trial data are the main drivers.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
G1 Therapeutics is an oncology company whose lead drug is designed to protect bone marrow from damage during chemotherapy. This is an important supportive therapy. The dynamics of the biotech sector underscore the overall context in which G1 Therapeutics is commercializing its product, aiming to make it a standard for patients undergoing certain treatments.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
G1 Therapeutics, Inc. is a commercial biopharmaceutical company focused on developing and marketing drugs that improve cancer treatment outcomes. The company's future depends on sales of its approved drug and success in R&D. The broader market chart serves as a backdrop to assess how these specific factors impacted its stock.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization GTHX
G1 Therapeutics is a commercial oncology company. Its weekly stock price is driven by sales reports for its approved drug for bone marrow protection during chemotherapy and clinical trial news.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
G1 Therapeutics develops drugs to improve the results of chemotherapy. The company operates in the important niche of supportive oncology therapy. The chart below helps determine whether the company's stock price fluctuations reflect its own commercial success and clinical data or reflect the overall sentiment in the sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
G1 Therapeutics is an oncology company. Its success depends on the sales of its drugs. This chart shows how its shares live their own lives, reacting to sales reports and research news rather than the market.
Market capitalization of the company, segment and market as a whole
GTHX - Market capitalization of the company GTHX
G1 Therapeutics' market capitalization chart reflects its focus on developing and commercializing drugs to improve chemotherapy outcomes. Its market valuation is based on the success of its first approved drug, Cosela. Its share price dynamics reflect investors' perceptions of its sales and the potential of its other developments.
GTHX - Share of the company's market capitalization GTHX within the market segment - General oncology therapy
G1 Therapeutics is a biotech company whose drug helps protect bone marrow during chemotherapy. Its market share in the oncology sector is small, but it already has a commercial product. The market capitalization chart reflects current sales of its drug and the market's assessment of the potential of its other developments.
Market capitalization of the market segment - General oncology therapy
The chart below shows the overall value of the biotech sector. G1 Therapeutics is a company that successfully developed and commercialized a drug that protects bone marrow from chemotherapy. Its market history exemplifies how a focus on supportive care can lead to the creation of an important and commercially successful product.
Market capitalization of all companies included in a broad market index - GURU.Markets
G1 Therapeutics develops small-molecule drugs to improve cancer treatment outcomes. Its market capitalization reflects the potential of its drugs in supportive care. The chart below shows the economic weight of companies working in this important field.
Book value capitalization of the company, segment and market as a whole
GTHX - Book value capitalization of the company GTHX
G1 Therapeutics's foundation is its intellectual property and commercial drug, COSELA, which protects bone marrow from chemotherapy damage. The chart tells the story of a biotech company that, after successfully launching its first product, uses the capital raised to advance its development and fund further development.
GTHX - Share of the company's book capitalization GTHX within the market segment - General oncology therapy
G1 Therapeutics develops drugs to protect bone marrow during chemotherapy. The chart shows its share of commercial and R&D assets. This includes its sales and marketing infrastructure, as well as the laboratories that form its physical base.
Market segment balance sheet capitalization - General oncology therapy
G1 Therapeutics is a biopharmaceutical company specializing in oncology. They focus on clinical research rather than manufacturing. A book value chart shows their modest R&D base, as their main asset is intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
G1 Therapeutics' resources include laboratories and R&D centers for developing drugs that protect bone marrow during chemotherapy. The chart shows how the company built its scientific and physical capital to bring its product to market.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - GTHX
G1 Therapeutics develops drugs to improve the results of chemotherapy. Its book value is primarily cash flow for further research. The chart below shows how the market values sales of the approved drug and the potential of other developments. This is an estimate of future cash flows, not current assets.
Market to book capitalization ratio in a market segment - General oncology therapy
G1 Therapeutics develops and commercializes drugs that help protect bone marrow from damage caused by chemotherapy. Its value is determined by the commercial success of its approved product. The chart shows how the market values the current and future sales of this drug, relating them to the company's assets.
Market to book capitalization ratio for the market as a whole
G1 Therapeutics develops drugs to improve the results of chemotherapy. Like many oncology companies, its market value reflects the potential of its lead drug. This metric represents the premium investors pay for the drug's commercial success over the company's book value.
Debts of the company, segment and market as a whole
GTHX - Company debts GTHX
G1 Therapeutics is a biopharmaceutical company that commercialized its first drug to protect bone marrow during chemotherapy. This chart shows how the company manages its finances. Sales revenues are reinvested in clinical research to expand the drug's use and fund other developments.
Market segment debts - General oncology therapy
G1 Therapeutics develops and commercializes drugs to improve the outcome of chemotherapy in cancer patients. The company already has an approved product but continues research. This chart shows how the company's financial strategy balances sales revenue with development costs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio GTHX
G1 Therapeutics is a biopharmaceutical company with an approved drug. This chart shows its financial structure. Having a commercial product allows for the use of moderate debt to fund marketing and further research. However, investors should keep an eye on sales growth.
Market segment debt to market segment book capitalization - General oncology therapy
G1 Therapeutics is a biopharmaceutical company developing drugs to improve the effectiveness of chemotherapy. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to finance the commercialization of its already approved products and further research.
Debt to book value of all companies in the market
G1 Therapeutics is a biopharmaceutical company developing drugs to improve the results of chemotherapy. Commercializing even adjuvant therapies requires investment. This chart of total market debt helps assess how aggressively the company uses debt capital to advance its products in the competitive oncology market.
P/E of the company, segment and market as a whole
P/E - GTHX
G1 Therapeutics is a biopharmaceutical company focused on developing and commercializing drugs to improve cancer treatment outcomes. This chart reflects investor valuations of its lead product, Cosela. The valuation is driven by sales volume and success in expanding its use.
P/E of the market segment - General oncology therapy
G1 Therapeutics is a biopharmaceutical company focused on developing and commercializing drugs to improve cancer treatment outcomes. Its flagship product helps protect bone marrow from chemotherapy-induced damage. This chart shows the average valuation for the oncology therapeutics sector, reflecting how investors value drugs that improve the safety and effectiveness of cancer treatment.
P/E of the market as a whole
G1 Therapeutics is a biopharmaceutical company specializing in developing drugs to improve cancer treatment outcomes. Its valuation depends on the commercial success of its approved drugs and research results. General market sentiment, reflected in this chart, has little impact on its business, which is driven by the specifics of the oncology market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company GTHX
G1 Therapeutics is a biopharmaceutical company focused on developing drugs to improve cancer treatment outcomes. This chart reflects expected future revenue from sales of its currently approved drug and the potential of its other developments. Commercial success is key to future profits.
%20P%2FE%20GTHX&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-GTHX&v=1772550912100 "Chart of the company's future (projected) P/E GTHX")
Future (projected) P/E of the market segment - General oncology therapy
G1 Therapeutics is a biopharmaceutical company focused on developing and commercializing drugs that improve the lives of cancer patients. Their lead product helps protect bone marrow from chemotherapy-induced damage. The chart reflects average expectations for the oncology segment. GTHX's position relative to this benchmark reflects the market's assessment of the commercial success of their drug.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772550912129 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecules to improve the lives of cancer patients. Its key product helps protect bone marrow from damage caused by chemotherapy. This chart of overall market expectations provides a framework for evaluating companies operating in the oncology supportive care market.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772550912175 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit GTHX
G1 Therapeutics is a biopharmaceutical company focused on developing and commercializing drugs to improve cancer treatment outcomes. Its financial performance, as shown in the graph, is driven by sales of its first approved drug, Cosela, which helps protect bone marrow during chemotherapy.
Profit of companies in the market segment - General oncology therapy
G1 Therapeutics is a biopharmaceutical company focused on developing and commercializing drugs to improve treatment outcomes for cancer patients. Its flagship product helps protect bone marrow during chemotherapy. This chart shows overall profitability in the oncology sector. It reflects the industry's success in developing supportive therapies that are becoming standard of care.
Overall market profit
G1 Therapeutics develops and commercializes drugs to improve treatment outcomes for cancer patients. Its flagship product helps protect bone marrow during chemotherapy. Demand for these drugs is driven by medical needs and is largely independent of economic cycles, as shown in this chart. However, the stability of the healthcare system is important.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company GTHX
G1 Therapeutics develops and commercializes drugs designed to improve cancer treatment outcomes. Its flagship product helps protect bone marrow from damage caused by chemotherapy. This chart shows analysts' expectations for sales growth for this drug and progress in developing other candidates.
%20profit%20of%20the%20company%20GTHX&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-GTHX&v=1772550912523 "Graph of future (projected) profit of the company GTHX")
Future (predicted) profit of companies in the market segment - General oncology therapy
G1 Therapeutics develops targeted therapies for cancer treatment, specifically to protect bone marrow from chemotherapy-induced damage. The company's success depends on the commercialization of its approved product and the development of new drugs. This chart shows forecasts for the entire biotech sector, providing context for assessing G1 Therapeutics' potential in supportive oncology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772550912599 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
G1 Therapeutics develops and markets drugs that improve the results of chemotherapy. Demand for these maintenance medications depends on the number of cancer patients and treatment standards. General economic cycles, reflected in this chart, have only an indirect impact on its business.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772550912655 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - GTHX
G1 Therapeutics is a biopharmaceutical company that already has an approved drug for bone marrow protection during chemotherapy. This chart shows how the market views the commercial launch and sales potential of this product. The trend reflects the company's success in introducing its drug into oncology practice.
P/S market segment - General oncology therapy
G1 Therapeutics develops and commercializes targeted therapies to improve treatment outcomes for cancer patients. Revenue is generated from sales of its approved product. This oncology sector chart helps assess how the market perceives the commercial success of G1's current drug and the potential of its future developments.
P/S of the market as a whole
G1 Therapeutics is a biopharmaceutical company focused on developing and commercializing drugs that improve cancer treatment outcomes. Its lead product helps protect bone marrow from damage during chemotherapy. This market revenue valuation chart helps understand how investors value a company with a commercial product in the field of oncology supportive care.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company GTHX
G1 Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative cancer treatments. Its lead product helps protect bone marrow from damage during chemotherapy. This chart shows how the market estimates future sales of this drug, reflecting expectations for its adoption in oncology practice.
%20P%2FS%20GTHX&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-GTHX&v=1772550912855 "The graph of the company's future (projected) P/S GTHX")
Future (projected) P/S of the market segment - General oncology therapy
G1 Therapeutics is a commercial-stage biopharmaceutical company whose drug, Cosela, helps protect bone marrow from damage during chemotherapy. The company's valuation reflects both the current sales of this product and investor expectations for its further clinical adoption and expansion into new markets.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772550912935 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
G1 Therapeutics develops drugs to improve cancer treatment outcomes. The company focuses on maintenance therapy. In the overall revenue growth picture illustrated by the chart, G1 represents an innovative sector that improves the effectiveness of chemotherapy.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772550912949 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales GTHX
G1 Therapeutics is a commercial-stage oncology company. This chart shows revenue from sales of its lead product, COSELA, which helps protect patients' bone marrow during chemotherapy. Successful commercialization and drug adoption by oncologists are key growth drivers.
Sales of companies in the market segment - General oncology therapy
G1 Therapeutics (GTHX) is a biopharmaceutical company focused on developing and commercializing drugs that improve the lives of cancer patients. Its flagship product, COSELA, protects bone marrow from chemotherapy-induced damage. This metric reflects revenue in the oncology sector. G1 Therapeutics creates innovative supportive therapies.
Overall market sales
G1 Therapeutics develops drugs aimed at improving the results of chemotherapy. Its commercial success depends on the acceptance of its products by oncologists. This pattern of overall economic activity impacts healthcare funding. A stable economy improves the ability of patients and insurers to pay for innovative supportive treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company GTHX
G1 Therapeutics is a biopharmaceutical company focused on developing and commercializing drugs to improve cancer treatment outcomes. Its lead product is designed to protect bone marrow during chemotherapy. This chart reflects analyst sales forecasts, which are estimates of the commercial success and market acceptance of its drug.
%20sales%20of%20the%20company%20GTHX&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-GTHX&v=1772550913350 "Schedule of future (projected) sales of the company GTHX")
Future (projected) sales of companies in the market segment - General oncology therapy
G1 Therapeutics is a biopharmaceutical company specializing in drugs to improve cancer treatment outcomes. This forecast chart details expected sales of their flagship product, which helps protect bone marrow during chemotherapy. It shows how analysts estimate demand for this supportive therapy.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772550913485 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
G1 Therapeutics develops drugs that help protect patients' bone marrow from damage during chemotherapy. This allows for more intensive cancer treatment. This graph illustrates general trends in oncology, and the commercial success of the company's drug is an indicator of the importance of supportive care in improving treatment outcomes.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772550913506 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality GTHX
G1 Therapeutics is a biopharmaceutical company focused on developing and commercializing drugs to improve cancer treatment outcomes. Its profitability depends on sales of its key drug, Cosela. The chart shows how the company translates its innovations in supportive cancer therapy into tangible financial returns.
Market segment marginality - General oncology therapy
G1 Therapeutics is a biopharmaceutical company focused on developing and commercializing drugs to improve treatment outcomes for cancer patients. Its key product, Cosela, helps protect bone marrow during chemotherapy. This chart shows the company's profitability. Success depends on Cosela's sales volume and its clinical adoption.
Market marginality as a whole
G1 Therapeutics is a biopharmaceutical company focused on developing drugs to improve cancer treatment outcomes. This overall profitability chart reflects the state of the healthcare system, which is crucial for the commercial success of its products. The financial stability of hospitals and insurers allows them to cover the costs of innovative drugs.
Employees in the company, segment and market as a whole
Number of employees in the company GTHX
G1 Therapeutics is a biopharmaceutical company that successfully developed and commercialized a drug that protects patients' bone marrow from damage during chemotherapy. This graph shows the team's progress through the full cycle, from research to commercialization, and is now focused on sales and marketing of their key product.
Share of the company's employees GTHX within the market segment - General oncology therapy
G1 Therapeutics is a biopharmaceutical company that has already commercialized a drug to protect bone marrow during chemotherapy. As a commercial company, its staff includes not only R&D but also a large sales and marketing department. This chart reflects its full operational cycle, from research to collaboration with oncology clinics across the country.
Number of employees in the market segment - General oncology therapy
G1 Therapeutics develops and commercializes drugs that improve cancer treatment outcomes. This chart, showing its work in oncology therapy, illustrates the company's ongoing search for new ways to fight the disease. For G1, whose drug helps protect bone marrow during chemotherapy, growth in this area means expanded use.
Number of employees in the market as a whole
G1 Therapeutics develops and commercializes drugs aimed at improving treatment outcomes for cancer patients. The company's success depends on demand for its products from oncology clinics. The growth in overall employment, reflected in this graph, supports the healthcare system through insurance premiums, providing funding for the purchase of innovative drugs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company GTHX (GTHX)
G1 Therapeutics (GTHX) is a biopharmaceutical company specializing in oncology. This chart is a sign of hope for biotech investors. The company's market value is almost entirely derived from its intellectual property and clinical development potential. The value per employee is high because it is not tied to physical production.
%20of%20the%20company%20GTHX%20(GTHX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-GTHX-GTHX&v=1772550913941 "Chart of market capitalization per employee (in thousands of dollars) of the company GTHX (GTHX)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
G1 Therapeutics is a biopharmaceutical company that already has an approved drug for bone marrow protection during chemotherapy. This metric reflects both the current sales of this product and the potential of other developments, which together create a high market value per employee.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772550914076 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
G1 Therapeutics is a biopharmaceutical company whose drug Cosela helps protect patients' bone marrow during chemotherapy. The company has an approved product. This chart for G1 Therapeutics illustrates how the successful commercialization of a single innovative drug can generate very high market value per employee.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772550914122 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company GTHX (GTHX)
G1 Therapeutics is a biotech company with an approved drug (Cosela). This chart shows how successful the company is in commercialization. It reflects a balance: is the profit from sales of a single drug high enough to cover all R&D and marketing costs per employee?
%20Chart%20GTHX%20(GTHX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-GTHX-GTHX&v=1772550914214 "Company Profit Per Employee (in thousands of dollars) Chart GTHX (GTHX)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
G1 Therapeutics develops drugs to improve treatment outcomes for cancer patients. In the field of supportive care in oncology, the effectiveness of the R&D team determines the company's success. This metric demonstrates the value each employee creates, which is an important indicator for assessing the company's potential to bring new drugs to market.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772550914254 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
G1 Therapeutics is a biopharmaceutical company focused on developing drugs (such as trilaciclib) that help protect bone marrow during chemotherapy. This chart measures the economy's average profit per employee. It provides investors with context: how efficient a pharmaceutical business, where one successful drug recoups R&D costs, is in terms of employee return.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772550914294 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee GTHX (GTHX)
G1 Therapeutics is a commercial biopharmaceutical company focused on oncology. Its revenue per employee is generated by sales of its first approved drug, Cosela. The chart shows how successfully the company's commercial team is promoting this innovative drug, which helps protect bone marrow during chemotherapy.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-GTHX-GTHX&v=1772550914308 "Sales chart per company employee GTHX (GTHX)")
Sales per employee in the market segment - General oncology therapy
G1 Therapeutics (GTHX) is a biopharmaceutical company specializing in oncology, best known for its drug Cosela, which protects bone marrow during chemotherapy. This chart shows the average revenue per employee in the segment. It helps assess how effectively G1 is commercializing its key drug.
Sales per employee for the market as a whole
G1 Therapeutics (GTHX) is a biopharmaceutical company focused on oncology. They already have an approved drug (Cosela) that protects bone marrow during chemotherapy. This metric demonstrates commercial success and shows how much revenue their R&D and specialty sales team generates from the sale of this innovative drug.
Short shares by company, segment and market as a whole
Shares shorted by company GTHX (GTHX)
G1 Therapeutics (GTHX) is an oncology company whose lead drug, Cosela (Trilaciclib), has had a very slow start to sales. This chart shows short interest. The rise in bearish bets reflects investor disappointment in Cosela's commercial potential and concerns that the company will be forced to burn cash without generating sufficient returns from its sole product. (348)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-GTHX-GTHX&v=1772550914476 "Short Shares Chart for the Company GTHX (GTHX)")
Shares shorted by market segment - General oncology therapy
G1 Therapeutics (GTHX) is a biopharmaceutical company specializing in drugs that improve cancer treatment outcomes (e.g., protecting bone marrow during chemotherapy). The chart below shows the overall short position in the oncology sector. It demonstrates the investor confidence in the commercial success of these supportive drugs.
Shares shorted by the overall market
G1 Therapeutics is a biotech that already has an approved drug (Cosela), but is still spending money on R&D and sales promotion. This chart measures overall fear. When investors are fearful, they doubt the success of new launches. They worry that during a recession, hospitals will cut corners and slowly roll out Cosela, which will slow GTHX's growth and increase cash burn.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator GTHX (GTHX)
G1 Therapeutics is a biotech company that already has an approved drug (Cosela) that protects bone marrow during chemotherapy. This indicator measures the "temperature" of commercialization. It "warms up" if Cosela sales are growing and "cools down" if market adoption is slow.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-GTHX-GTHX&v=1772550914608 "RSI 14 indicator chart for the company's stock GTHX (GTHX)")
RSI 14 Market Segment - General oncology therapy
G1 Therapeutics is a commercial-stage biopharmaceutical company focused on oncology. Its approved drug, Cosela (Trilaciclib), is used to protect bone marrow during chemotherapy. This chart shows the overall sentiment in the oncology biotech sector. It helps us understand whether G1 Therapeutics' momentum is driven by its commercial success or is a general "wave" across the industry.
RSI 14 for the overall market
G1 Therapeutics (GTHX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GTHX (GTHX)
G1 Therapeutics is a biopharmaceutical company whose key approved drug (Cosela) is used for "myeloprotection," protecting patients' bone marrow during chemotherapy. This chart shows the average analyst price target, which is almost entirely based on their forecasts for sales growth and adoption of Cosela in oncology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GTHX-GTHX&v=1772550914751 "A chart showing analyst consensus forecasts for the expected stock price. GTHX (GTHX)")
The difference between the consensus estimate and the actual stock price GTHX (GTHX)
G1 Therapeutics is a champion of chemotherapy. Their flagship drug (Cosela) is a first-in-class drug that protects bone marrow during lung cancer treatment. This chart measures the gap between the current price and the consensus target price. It shows whether experts believe this drug will be commercially successful and expand its use.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GTHX-GTHX&v=1772550914878 "A chart showing the difference between the consensus forecast and the actual stock price. GTHX (GTHX)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
G1 Therapeutics is a biotech company whose lead drug (Cosela) is used to protect patients' bone marrow during chemotherapy. This chart reflects analysts' overall expectations for the oncology sector. It shows whether experts believe the market for "companion" therapies in cancer treatment will grow.
Analysts' consensus forecast for the overall market share price
G1 Therapeutics is a biotech company whose key product is a drug (Cosela) that protects patients' bone marrow during chemotherapy. This chart shows overall market sentiment. For G1, as a company in the commercialization stage, overall optimism is important for funding, but their growth depends more on the acceptance of their new drug by doctors and insurers.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index GTHX
G1 Therapeutics (GTHX) is a biotech R&D company that has crossed the finish line. Their signature drug (Cosela) is the world's first protective drug that protects bone marrow from damage during chemotherapy. This chart is a summary of their commercialization history. It reflects their (very slow) sales growth rate and their R&D efforts to expand the applications of their sole asset.
AKIMA Market Segment Index - General oncology therapy
G1 Therapeutics is an oncology company. Their drug Cosela (trilaciclib) is used to protect patients' bone marrow during chemotherapy. It is a general oncology therapy aimed at improving quality of life. This chart compares their composite index to the sector, showing how their protective approach outperforms the competition.
The AKIM Index for the overall market
G1 Therapeutics is a commercial-stage biopharmaceutical company marketing COSELA, a chemotherapy-associated bone marrow protection product. It is being acquired by Pharmacosmos. This chart, which reflects the market average, provides a macro backdrop. It helps assess how GTHX, a successful niche company, fared against the backdrop of broader economic trends before the acquisition.
